Larazotide, also known by its development code AT-1001, is an orally administered peptide compound. It is being investigated for its potential role in managing conditions characterized by increased intestinal permeability, often referred to as "leaky gut." Larazotide is designed to block the functional activity of zonulin, a human protein that modulates intestinal tight junctions. By doing so, it aims to reduce the passage of undigested food particles, toxins, and microbes from the gut lumen into the bloodstream. Currently, larazotide is an investigational compound and is not approved for clinical use by regulatory bodies such as the FDA or EMA. Its development has primarily focused on celiac disease, where increased intestinal permeability is a prominent feature.
Deep dive
Tap a section to expand.
Known interactions
Category rule: peptide × hormone
Note
Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.
Track bloodwork with a provider; don't assume combinations are neutral.
Frequently asked
Sources referenced
["DrugBank Online", "PubChem (National Library of Medicine)", "NIH Office of Dietary Supplements (referencing general information on peptides and gut health)", "Cochrane Database of Systematic Reviews", "ClinicalTrials.gov (for study information)"]
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the peptide category or studied for the same goals.